We examined the underlying relationship between fracture risk factors and their imminent risk. Results suggested that having past year fracture, worse past year general health, worse past year physical functioning, and lower past year BMD T-score directly predicted higher imminent fracture risk. Past year falls indirectly predicted imminent risk through physical functioning and general health.
This study aimed to examine direct and indirect effects of several factors on imminent (1 year) fracture risk.
Data from women age 65 and older from population-based Canadian Multicentre Osteoporosis Study were used. Predictors were identified from study years 5 and 10, and imminent fracture data (1-year fracture) came from years 6 and 11 (year 5 predicts year 6, year 10 predicts year 11). A structural equation model (SEM) was used to test the theoretical construct. General health and physical functioning were measured as latent variables using items from the 36-Item Short Form Health Survey (SF-36) and bone mineral density (BMD) T-score was a latent variable based on observed site-specific BMD data (spine L1-L4, femoral neck, total hip). Observed variables were fractures and falls. Model fit was evaluated using root mean square error of approximation (RMSEA), Tucker Lewis index (TLI), and comparative fit index (CFI).
The analysis included 3298 women. Model fit tests showed that the SEM fit the data well; χ2(172) = 1122.10 < .001, RMSEA = .03, TLI = .99, CFI = .99. Results suggested that having past year fracture, worse past year general health, worse past year physical functioning, and lower past year BMD T-score directly predicted higher risk of fracture in the subsequent year (p < .001). Past year falls had a statistically significant but indirect effect on imminent fracture risk through physical functioning and general health (p < .001).
We found several direct and indirect pathways that predicted imminent fracture risk in elderly women. Future studies should extend this work by developing risk scoring methods and defining imminent risk thresholds.
This is a preview of subscription content, log in to check access.
Buy single article
Instant access to the full article PDF.
Price includes VAT for USA
Subscribe to journal
Immediate online access to all issues from 2019. Subscription will auto renew annually.
This is the net price. Taxes to be calculated in checkout.
Note, the terms “direct effect” and “indirect effect” are standard terms used in SEM to describe the relationship between variables. If a relationship is observed “directly” between two variables it is a “direct effect”. If a relationship is mediated by one or more variables, it is an “indirect effect.” The term “effect” is not intended to suggest a causal relationship.
Singer A, Exuzides A, Spangler L, O’Malley C, Colby C, Johnston K, Agodoa I, Baker J, Kagan R (2015) Burden of illness for osteoporotic fractures compared with other serious diseases among postmenopausal women in the United States. In: Mayo Clinic Proceedings, vol 1. Elsevier, pp 53–62
de Luise C, Brimacombe M, Pedersen L, Sørensen HT (2008) Comorbidity and mortality following hip fracture: a population-based cohort study. Aging Clin Exp Res 20(5):412–418
Solomon DH, Johnston SS, Boytsov NN, McMorrow D, Lane JM, Krohn KD (2014) Osteoporosis medication use after hip fracture in US patients between 2002 and 2011. J Bone Miner Res 29(9):1929–1937
Khosla S, Cauley JA, Compston J, Kiel DP, Rosen C, Saag KG, Shane E (2017) Addressing the crisis in the treatment of osteoporosis: a path forward. J Bone Miner Res 32(3):424–430
Papaioannou A, Morin S, Cheung AM, Atkinson S, Brown JP, Feldman S, Hanley DA, Hodsman A, Jamal SA, Kaiser SM (2010) 2010 clinical practice guidelines for the diagnosis and management of osteoporosis in Canada: summary. Can Med Assoc J 182(17):1864–1873
Yusuf AA, Matlon TJ, Grauer A, Barron R, Chandler D, Peng Y (2016) Utilization of osteoporosis medication after a fragility fracture among elderly Medicare beneficiaries. Arch Osteoporos 11(1):31
Roux C, Briot K (2017) Imminent fracture risk. Osteoporos Int:1–5
Alami S, Hervouet L, Poiraudeau S, Briot K, Roux C (2016) Barriers to effective postmenopausal osteoporosis treatment: a qualitative study of patients’ and practitioners’ views. PLoS One 11(6):e0158365
Kanis JA, Harvey NC, Cooper C, Johansson H, Odén A, McCloskey EV (2016) A systematic review of intervention thresholds based on FRAX. Arch Osteoporos 11(1):25
Siris E, Delmas P (2008) Assessment of 10-year absolute fracture risk: a new paradigm with worldwide application. Springer,
Kanis JA, Harvey NC, Johansson H, Odén A, McCloskey EV, Leslie WD (2017) Overview of fracture prediction tools. J Clin Densitom
Bonafede M, Shi N, Barron R, Li X, Crittenden D, Chandler D (2016) Predicting imminent risk for fracture in patients aged 50 or older with osteoporosis using US claims data. Arch Osteoporos 11(1):26
Johansson H, Siggeirsdóttir K, Harvey NC, Odén A, Gudnason V, McCloskey E, Sigurdsson G, Kanis JA (2017) Imminent risk of fracture after fracture. Osteoporos Int 28(3):775–780
van Geel TA, van Helden S, Geusens PP, Winkens B, Dinant G-J (2009) Clinical subsequent fractures cluster in time after first fractures. Ann Rheum Dis 68(1):99–102
O’Hanlon CE, Parthan A, Kruse M, Cartier S, Stollenwerk B, Jiang Y, Caloyeras JP, Crittenden DB, Barron R (2017) A model for assessing the clinical and economic benefits of bone-forming agents for reducing fractures in postmenopausal women at high, near-term risk of osteoporotic fracture. Clin Ther 39(7):1276–1290
Cosman F, Nieves JW, Dempster DW (2017) Treatment sequence matters: anabolic and antiresorptive therapy for osteoporosis. J Bone Miner Res 32(2):198–202
Leder BZ (2018) Optimizing sequential and combined anabolic and antiresorptive osteoporosis therapy. JBMR Plus 2(2):62–68. https://doi.org/10.1002/jbm4.10041
Cosman F, Miller PD, Williams GC, Hattersley G, Hu M-Y, Valter I, Fitzpatrick LA, Riis BJ, Christiansen C, Bilezikian JP (2017) Eighteen months of treatment with subcutaneous abaloparatide followed by 6 months of treatment with alendronate in postmenopausal women with osteoporosis: results of the ACTIVExtend trial. In: Mayo Clinic Proceedings, vol 2. Elsevier, pp 200–210
Cosman F, Crittenden DB, Adachi JD, Binkley N, Czerwinski E, Ferrari S, Hofbauer LC, Lau E, Lewiecki EM, Miyauchi A (2016) Romosozumab treatment in postmenopausal women with osteoporosis. N Engl J Med 375(16):1532–1543
Hippisley-Cox J, Coupland C (2012) Derivation and validation of updated QFracture algorithm to predict risk of osteoporotic fracture in primary care in the United Kingdom: prospective open cohort study. Bmj 344:e3427
Leslie WD, Majumdar SR, Morin SN, Lix LM, Johansson H, Oden A, McCloskey EV, Kanis JA (2017) FRAX for fracture prediction shorter and longer than 10 years: the Manitoba BMD registry. Osteoporos Int 28(9):2557–2564. https://doi.org/10.1007/s00198-017-4091-3
Nguyen ND, Frost SA, Center J, Eisman JA, Nguyen TV (2008) Development of prognostic nomograms for individualizing 5-year and 10-year fracture risks. Osteoporos Int 19(10):1431–1444
van Geel TA, Eisman JA, Geusens PP, van den Bergh JP, Center JR, Dinant G-J (2014) The utility of absolute risk prediction using FRAX® and Garvan fracture risk calculator in daily practice. Maturitas 77(2):174–179
Duncan OD (2014) Introduction to structural equation models. Elsevier,
Acock AC (2013) Discovering structural equation modeling using Stata. Stata Press books
Kreiger N, Tenenhouse A, Joseph L, Mackenzie T, Poliquin S, Brown JP, Prior JC, Rittmaster RS (1999) The Canadian multicentre osteoporosis study (CaMos): background, rationale, methods. Canadian Journal on Aging/La Revue canadienne du vieillissement 18(3):376–387
Ware Jr JE, Sherbourne CD (1992) The MOS 36-item short-form health survey (SF-36): I. Conceptual framework and item selection Med Care:473–483
Cronbach LJ (1951) Coefficient alpha and the internal structure of tests. Psychometrika 16(3):297–334
Muthñn L, Muthñn B (2012) Mplus. Statistical analysis with latent variables User’s guide seventh edition. Muthñn & Muthñn, Los Angeles
Wirth R, Edwards MC (2007) Item factor analysis: current approaches and future directions. Psychol Methods 12(1):58–79
Browne MW, Cudeck R (1989) Single sample cross-validation indices for covariance structures. Multivar Behav Res 24(4):445–455
Hu L, Bentler PM (1999) Cutoff criteria for fit indexes in covariance structure analysis: conventional criteria versus new alternatives. Struct Equ Model Multidiscip J 6(1):1–55
Balasubramanian A, Zhang J, Chen L, Wenkert D, Daigle S, Grauer A, Curtis J (2019) Risk of subsequent fracture after prior fracture among older women. Osteoporos Int 30(1):79–92
Miller PD, Hattersley G, Riis BJ, Williams GC, Lau E, Russo LA, Alexandersen P, Zerbini CA, Hu M-y, Harris AG (2016) Effect of abaloparatide vs placebo on new vertebral fractures in postmenopausal women with osteoporosis: a randomized clinical trial. Jama 316(7):722–733
Kendler DL, Marin F, Zerbini CA, Russo LA, Greenspan SL, Zikan V, Bagur A, Malouf-Sierra J, Lakatos P, Fahrleitner-Pammer A (2017) Effects of teriparatide and risedronate on new fractures in post-menopausal women with severe osteoporosis (VERO): a multicentre, double-blind, double-dummy, randomised controlled trial. Lancet
Stone KL, Seeley DG, Lui LY, Cauley JA, Ensrud K, Browner WS, Nevitt MC, Cummings SR (2003) BMD at multiple sites and risk of fracture of multiple types: long-term results from the Study of Osteoporotic Fractures. J Bone Miner Res 18(11):1947–1954
This study was funded by Amgen Inc. and UCB Pharma. Sponsors of CaMos have included Actavis, Amgen Inc., the Arthritis Society, the Canadian Institutes of Health Research (CIHR), Dairy Farmers of Canada, Merck, Eli Lilly, Novartis, P&G, Sanofi-Aventis, and Servier.
Conflicts of interest
AP receives grants and speaking honoraria from Amgen Inc. JDA receives grants, consulting fees, and speaking honoraria from Amgen Inc. YJ was an employee of Amgen Inc. when the submitted work was conducted and is presently an associate professor with Sun Yat-sen University School of Public Health (Shenzhen). RB is an employee of Amgen Inc. and holds stocks of Amgen Inc. JSM is an employee of Vector Psychometrics Group, LLC. RJW is an employee of Vector Psychometrics Group, LLC. DAH receives speaking honoraria from Amgen Inc. and has been a local principal investigator for a multinational clinical trial sponsored by Amgen Inc. SMK receives consulting fees from Amgen Inc., Merck, Eli Lilly, speaking honoraria from Amgen Inc., Merck, Sanofi, and has been a clinical trial investigator of studies sponsored by Amgen Inc., Eli Lilly, and Merck. SNM receives grants from Amgen Inc. and Merck & Co., Inc. TT receives consulting fees from Amgen Inc. DG receives grants from Amgen Inc. and Eli Lilly & Co. and consulting fees from Amgen Inc. CB, TPA, KSD, GI, CSK, WDL, and JCP claim no conflicts of interests.
For this type of study, formal consent is not required. The submitted work is a post hoc analysis of CaMos data. For the primary CaMos study, ethics approval was granted through McGill University and the appropriate research ethics board for each of the 9 participating centers. Signed informed consent was obtained from every study participant in accordance with the Helsinki Declaration.
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
About this article
Cite this article
Papaioannou, A., Adachi, J.D., Berger, C. et al. Testing a theoretical model of imminent fracture risk in elderly women: an observational cohort analysis of the Canadian Multicentre Osteoporosis Study. Osteoporos Int (2020). https://doi.org/10.1007/s00198-020-05330-2
- fracture risk
- older women